1- (2- (morpholin- 4- yl)ethyl)- 3- (4- (- 3- (6- (morpholin- 4- yl)pyridin- 2-yl)prop-2-enoyl)phenyl)urea dihydrochloride

structure in first source

Also Known As:

TRC051384

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - 1-(2-(morpholin-4-yl)ethyl)-3-(4-(-3-(6-(morpholin-4-yl)pyridin- 2-yl)prop-2-enoyl)phenyl)urea dihydrochloride: 2
  - Oxazines: 9
    - Morpholines: 6
      - 1-(2-(morpholin-4-yl)ethyl)-3-(4-(-3-(6-(morpholin-4-yl)pyridin- 2-yl)prop-2-enoyl)phenyl)urea dihydrochloride: 2
Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - 1-(2-(morpholin-4-yl)ethyl)-3-(4-(-3-(6-(morpholin-4-yl)pyridin- 2-yl)prop-2-enoyl)phenyl)urea dihydrochloride: 2

Experts

1.	Chauthaiwale, Vijay: 1 article (05/2011)
2.	Deshpande, Shailesh: 1 article (05/2011)
3.	Dutt, Chaitanya: 1 article (05/2011)
4.	Gupta, Ramesh C: 1 article (05/2011)
5.	Jamadarkhana, Prashant G: 1 article (05/2011)
6.	Kumar, Prabhat: 1 article (05/2011)
7.	Mohanan, Anookh: 1 article (05/2011)

Related Diseases

1.	Ischemia 05/01/2011 - "Significant improvement in survival (50% by day 2 and 67.3% by day 7) was observed with TRC051384 treatment initiated at 4 hours after ischemia onset. " 05/01/2011 - "Rats subjected to 2 hours focal cerebral ischemia were administered by intra-peritoneal route, TRC051384 or vehicle every 2 hours for 48 hours, from 4th hour or 8th hour after onset of ischemia. " 05/01/2011 - "The aim of this study was to investigate the ability of TRC051384 in reducing neuronal injury and disability upon delayed treatments (4 and 8 hours post ischemia onset) in a rat model of transient cerebral ischemia. " 05/01/2011 - "Here we show for the first time that treatment with TRC051384 significantly reduces stroke associated neuronal injury (87% reduction in area of penumbra recruited to infarct, and 25% reduction in brain edema) and disability in a rat model of transient ischemic stroke even when administered 8 hours post onset of ischemia. "
2.	Transient Ischemic Attack 05/01/2011 - "The aim of this study was to investigate the ability of TRC051384 in reducing neuronal injury and disability upon delayed treatments (4 and 8 hours post ischemia onset) in a rat model of transient cerebral ischemia. "
3.	Stroke (Strokes) 05/01/2011 - "Here we show for the first time that treatment with TRC051384 significantly reduces stroke associated neuronal injury (87% reduction in area of penumbra recruited to infarct, and 25% reduction in brain edema) and disability in a rat model of transient ischemic stroke even when administered 8 hours post onset of ischemia. "
4.	Wounds and Injuries (Trauma) 09/01/2023 - "The results of immunostaining and lactate dehydrogenase release assay showed that necroptosis following neuronal trauma was inhibited by HSP70 activator TRC051384 (TRC), but promoted by the HSP70 inhibitor 2-phenylethyenesulfonamide (PES). "
5.	Infarction (Infarctions) 05/01/2011 - "Here we show for the first time that treatment with TRC051384 significantly reduces stroke associated neuronal injury (87% reduction in area of penumbra recruited to infarct, and 25% reduction in brain edema) and disability in a rat model of transient ischemic stroke even when administered 8 hours post onset of ischemia. "

Related Drugs and Biologics

1.	L-Lactate Dehydrogenase (Lactate Dehydrogenase)

Related Therapies and Procedures

1.	Treatment Delay